Nijmegen-based Alveron Pharma, a clinical-stage company developing innovative treatments for intracranial haemorrhage (ICH), has secured €5 million in a Series Seed extension funding round.
The investment was led by Broadview Ventures, with participation from existing backers Sanquin, Thuja Capital, Waterman Ventures, and Oost NL.
Accelerating Development of OKL-1111
The funds will be used to advance OKL-1111, Alveron Pharma’s synthetic drug designed to reverse the effects of anticoagulants and platelet inhibitors. The drug aims to prevent hematoma expansion and improve outcomes for ICH patients by providing a universal action that binds to a specific clotting factor.
Current treatments for ICH patients often take over two hours to administer, leading to delayed results. In contrast, OKL-1111 can be administered within 10 minutes of a CT scan diagnosis, offering significant advantages in speed and effectiveness. It also provides an antidote for clopidogrel, a commonly used platelet inhibitor that currently lacks a reversal agent.
Ben Nichols, CEO of Alveron Pharma, stated: “With the support of our specialist life science investors and Scientific Advisory Board, we are eager to bring our innovative therapeutic approach to patients, improving outcomes and addressing a critical unmet medical need.”mia, and leverage CompactifAI to create efficient and portable solutions for large-language models.”
Advertisement
Backing from Broadview Ventures
Broadview Ventures focuses on early-stage companies developing therapeutics, devices, and diagnostics for cardiovascular diseases and stroke.
Benjamin Kreitman, Principal at Broadview Ventures, emphasized: “Intracranial haemorrhage represents a severe unmet medical need. Alveron’s novel approach to reversing anticoagulants and platelet inhibitors could deliver meaningful improvements for patients, aligning perfectly with our mission to improve human health in cardiovascular and stroke care.”
Addressing a Critical Need in Stroke Management
Founded in 2019, Alveron Pharma is dedicated to developing innovative therapies for life-threatening conditions. With this funding, the company is poised to advance its clinical studies, paving the way for the safe and effective treatment of ICH and related complications.
